Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:CARANASDAQ:DYNNASDAQ:ENTANASDAQ:HGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.81+13.8%$2.16$1.29▼$7.85$270.99M1.31.45 million shs3.09 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4123,064 shs237,144 shsDYNDyne Therapeutics$8.94+3.0%$11.77$6.36▼$47.45$986.63M1.081.81 million shs5.56 million shsENTAEnanta Pharmaceuticals$7.97+3.5%$6.40$4.09▼$17.24$164.60M0.84282,907 shs209,818 shsHGENHumanigen$0.00$0.00▼$0.24$24K-1.043.26 million shs2.06 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+2.92%+0.82%+18.18%+26.02%-51.09%CARACara Therapeutics0.00%0.00%0.00%+4.31%+68.57%DYNDyne Therapeutics-8.82%-18.34%-26.57%-12.41%-75.54%ENTAEnanta Pharmaceuticals+1.85%+5.19%+28.98%+45.28%-41.09%HGENHumanigen0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.233 of 5 stars3.51.00.00.03.12.50.0CARACara Therapeutics0.3168 of 5 stars0.00.00.04.20.60.80.0DYNDyne Therapeutics3.4938 of 5 stars4.53.00.00.02.52.50.0ENTAEnanta Pharmaceuticals4.102 of 5 stars3.42.00.04.72.62.50.0HGENHumanigenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$12.50344.84% UpsideCARACara Therapeutics 0.00N/AN/AN/ADYNDyne Therapeutics 3.00Buy$41.13360.01% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$18.00125.85% UpsideHGENHumanigen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HGEN, DYN, ANNX, CARA, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/25/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/24/2025DYNDyne TherapeuticsSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$13.006/18/2025DYNDyne TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/18/2025DYNDyne TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.006/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/11/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/3/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.006/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/14/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $14.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/ACARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00DYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AENTAEnanta Pharmaceuticals$67.64M2.52N/AN/A$6.08 per share1.31HGENHumanigen$1.70M0.00N/AN/A($0.45) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.18N/AN/AN/AN/A-54.45%-46.56%8/11/2025 (Estimated)CARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ADYNDyne Therapeutics-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)HGENHumanigen-$70.73MN/A0.00N/AN/AN/AN/AN/AN/ALatest HGEN, DYN, ANNX, CARA, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ANNXAnnexon-$0.30-$0.37-$0.07-$0.37N/AN/A5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AHGENHumanigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A7.997.99CARACara TherapeuticsN/A4.774.71DYNDyne TherapeuticsN/A20.3520.35ENTAEnanta PharmaceuticalsN/A5.295.29HGENHumanigenN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ACARACara Therapeutics44.66%DYNDyne Therapeutics96.68%ENTAEnanta Pharmaceuticals94.99%HGENHumanigen4.55%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%CARACara Therapeutics3.10%DYNDyne Therapeutics14.14%ENTAEnanta Pharmaceuticals13.89%HGENHumanigen21.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million96.69 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableDYNDyne Therapeutics100113.67 million97.59 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableHGENHumanigen6119.08 million93.24 millionNo DataHGEN, DYN, ANNX, CARA, and ENTA HeadlinesRecent News About These CompaniesFormer Humanigen director arrested for insider tradingDecember 25, 2024 | msn.comUS says former Humanigen chief scientific officer charged with insider tradingDecember 23, 2024 | reuters.comHumanigen, Inc. (HGEN)October 10, 2024 | finance.yahoo.comDrugmaker Accused of Overhyping Proposed COVID Treatment Agrees to $3M SettlementSeptember 18, 2024 | law.comLHumanigen Settles Investor Suit Over Rejected Covid-19 TreatmentSeptember 16, 2024 | news.bloomberglaw.comN0KB1.SG,0P00011RKD,0 (0KB1.SG)August 4, 2024 | ca.finance.yahoo.comEyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make itAugust 1, 2024 | pharmaphorum.comPHumanigen Aktie: Davon sollte man die Finger lassenMarch 28, 2024 | aktiencheck.deAHumanigen Aktie: Da kann man nur noch staunenMarch 24, 2024 | aktiencheck.deAHumanigen Inc (0KB2.BE)March 24, 2024 | finance.yahoo.comLevi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action SettlementMarch 5, 2024 | accesswire.comALevi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action SettlementFebruary 29, 2024 | accesswire.comAHumanigen Inc HGENQFebruary 6, 2024 | morningstar.comMLevi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action SettlementJanuary 25, 2024 | markets.businessinsider.comFirm Retention Summary: HumanigenJanuary 17, 2024 | wsj.comHumanigen Downfall: FDA Rejection For COVID-19 Drug Triggers Financial Crisis, BankruptcyJanuary 5, 2024 | msn.comCOVID-19 treatment developer Humanigen files for Chapter 11 bankruptcyJanuary 4, 2024 | news.yahoo.comCovid-19 Treatment Developer Humanigen Files for BankruptcyJanuary 4, 2024 | wsj.comCOVID pick Humanigen files for bankruptcyJanuary 4, 2024 | msn.comAktueller Chart HUMANIGEN AktieDecember 9, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure BoomJoby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsBy Jeffrey Neal Johnson | June 4, 2025View Joby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsSteel Dynamics Shares Climb After Tariff AnnouncementBy Dan Schmidt | June 3, 2025View Steel Dynamics Shares Climb After Tariff AnnouncementHGEN, DYN, ANNX, CARA, and ENTA Company DescriptionsAnnexon NASDAQ:ANNX$2.81 +0.34 (+13.77%) Closing price 04:00 PM EasternExtended Trading$2.88 +0.07 (+2.46%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Dyne Therapeutics NASDAQ:DYN$8.94 +0.26 (+3.00%) Closing price 04:00 PM EasternExtended Trading$8.80 -0.14 (-1.51%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$7.97 +0.27 (+3.51%) Closing price 04:00 PM EasternExtended Trading$7.97 0.00 (0.00%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Humanigen NASDAQ:HGENHumanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
